載入...
Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization
Oncolytic virotherapies, including the modified herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune effects. The OPTiM trial, in particular, demonstrated the superior anti-cancer effects of T-VEC as compared to systemic immunoth...
Na minha lista:
| 發表在: | PLoS Comput Biol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6880985/ https://ncbi.nlm.nih.gov/pubmed/31774808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pcbi.1007495 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|